The FDA announced new, lower dose labeling for Ambien, which is also known as zolpidem. The goal is to cut down on daytime drowsiness that could be a hazard while performing certain tasks such as driving.
The FDA is asking the manufacturers to cut the recommended doses for women in half and to consider prescribing lower doses for men. Women reportedly eliminate zolpidem more slowly from their bodies.
These changes were spurred by new driving simulation studies showing that current prescribed levels impair alertness the next day.
